Американское общество гирудотерапии

Latin America Multidisciplinary Consensus Panel on Management of Severe Bleeding in the Anticoagulated Patient

Review published in The Journal of emergency medicine (2025)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewКлинические исследованияФармакология секрета слюнных желёзPontes-Neto OM et al. · The Journal of emergency medicine, 2025

Abstract

BACKGROUND: Bleeding is the most important complication associated with anticoagulants. Patients experiencing bleeding while on an anticoagulation require proper risk stratification, which involves careful assessment of multiple factors, including hemodynamic stability, the origin of bleeding, and the extent of blood loss. Over the last several decades, important advances have been made in the field of anticoagulant therapy and reversal. OBJECTIVES: This manuscript provides a review of anticoagulant related hemorrhages, with particular emphasis on topics most relevant to Latin America. It offers an updated assessment of evidence-based strategies for managing major bleeding related to anticoagulation. We will also explore what happens to patients in real-life situations, where there are not specific reversal agents available. DISCUSSION: While minor bleeding can usually be managed simply by discontinuing the anticoagulant, major bleeding is a medical emergency that may threaten life and require the administration of blood products and the utilization of specific antidotes. Fresh frozen plasma (FFP) or prothrombin complex concentrates (PCCs) can be administrated for major bleeding incidents linked to warfarin. Protamine sulfate is administrated for unfractionated heparin and partially for low-molecular-weight heparin (LMWH). Idarucizumab is the reversal agent for dabigatran, while andexanet alfa is approved for the reversal of oral factor Xa inhibitors. CONCLUSIONS: This review highlights the significance of appropriate risk stratification and management strategies for bleeding complications associated with anticoagulants. The manuscript emphasizes the need for adaptable management strategies in regions like Latin America, where resource limitations may impact the availability of specific reversal agents.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReviewConsensus Statement
Indexed MeSH termsHumansAnticoagulantsLatin AmericaHemorrhageHeparin, Low-Molecular-WeightDabigatranWarfarinBlood Coagulation FactorsAntibodies, Monoclonal, Humanized

Резюме

Bleeding is the most important complication associated with anticoagulants.

Почему это важно для гирудотерапии

This review provides an updated assessment of evidence-based strategies for managing major bleeding related to anticoagulants, emphasizing proper risk stratification and the use of agents such as fresh frozen plasma, prothrombin complex concentrates, protamine sulfate, idarucizumab, and andexanet alfa, with particular attention to regions like Latin America where specific reversal agents may be unavailable. It is only indirectly relevant to hirudotherapy in that it addresses general principles of anticoagulant-related bleeding management. However, the manuscript does not mention hirudotherapy, leeches, or hirudin at any point. Its relevance to ASH's domain is therefore strictly background-level, providing no direct clinical guidance for leech application or leech-secretome-related bleeding.

Цитирование

Latin America Multidisciplinary Consensus Panel on Management of Severe Bleeding in the Anticoagulated Patient

Pontes-Neto OM et al. · The Journal of emergency medicine, 2025

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.